Fig. 1 · Structure

Documents & Downloads

Ciclopirox

Cat. No. A10213 CAS 29342-05-0
Ciclopirox is currently being investigated as an alternative treatment to ketoconazole for seborrhoeic dermatitis as it suppresses growth of the yeast Malassezia furfur.It acts by inhibiting the membrane transfer system by interrupting the Na+ K+ ATPase.

In Stock

Publications for Ciclopirox

1 publication citing this product

  1. Katsuhisa Morita, .et al. , Sci Rep, 2020, 10: 13139 PMID: 32753643

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
ATPase

Cellular Effect

Cell Line Activity Value Description Reference
Astrocyte IC50 0.33 μM Inhibition of H2O2-induced mitochondrial metabolic dysfunction in Sprague-Dawley rat primary astrocytes by resazurin-dye based presto blue assay [PMID: 28089588]
Astrocyte IC50 249.9 nM Cytoprotective activity in Sprague-Dawley rat primary astrocytes assessed as inhibition of H2O2-induced cell death by LDH release assay [PMID: 28089588]
HEK293 IC50 > 500 μM Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
Vero CC50 > 100 μM Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay [PMID: 35635945]

Ciclopirox Research Summary

This section summarizes 2 in vitro studies of Ciclopirox from 1 published reference. In vitro models include human hepatic cancer-derived HepG2 and HuH7 cell lines.

Ciclopirox In Vitro Studies

Ciclopirox produced cell-dependent ER-stress marker responses in hepatic cancer cell lines. It increased XBP1 splicing in HuH7 cells but not HepG2 cells; the HuH7 concentration response was non-monotonic. At 150 µM for 24 h, CHOP mRNA increased in HuH7 cells without a significant GRP78 increase. [1]

In primary human PXB hepatocytes, 150 µM ciclopirox for 24 h did not significantly increase XBP1 splicing or GRP78 mRNA, although CHOP mRNA showed a small significant increase. These findings limit extrapolation of the HuH7 response to primary hepatocytes. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell-dependent ER-stress marker responses in HepG2 and HuH7 cells

Cell-based study · Human hepatic cancer-derived HepG2 and HuH7 cell lines [1]

Ciclopirox increased XBP1 splicing in HuH7 cells, with a non-monotonic concentration profile, but did not increase splicing in HepG2 cells. At 150 µM, HuH7 CHOP mRNA increased without a significant GRP78 increase; corresponding HepG2 markers were not significantly increased. DMSO was the vehicle comparator; ciclosporin A and the candidate ER-stress-inducing compounds provided active comparisons.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ratio of spliced to unspliced XBP1 after 6 hQualitative response versus DMSO HuH7: increased at the higher tested concentrations, with a non-monotonic profile; at 10-fold concentration, ***P < 0.001. HepG2: no increase detected.[1]
GRP78 and CHOP mRNA relative to GAPDH after 24 h at 150 µMQualitative response versus DMSO HuH7: CHOP increased (*P < 0.05); GRP78 not significantly increased. HepG2: neither marker significantly increased.[1]

Literature-Reported Treatment Conditions

Treatment concentration
XBP1 assay: 1, 3 and 10 times the 15 µM transcriptome-dataset concentration (15, 45 and 150 µM); qPCR: 10 times (150 µM). Absolute values are arithmetic from Figure 2a and SI S8-S9/Figure 4 captions.
Exposure duration
6 h for XBP1 splicing; 24 h for GRP78 and CHOP mRNA
Method
Compound exposure followed by conventional PCR and MultiNA quantification of spliced/unspliced XBP1; qPCR markers normalized to GAPDH.
Vehicle
DMSO control; final vehicle percentage not specified in the inspected methods/captions.
Reported limits
Exact effect sizes and replicate hierarchy were not extracted from raw data. This is not an IC50 assay.
Methods and source locations

Compound reported in the paper: Ciclopirox; Compound label in the paper: CPX; AdooQ A10213-10

Cellular ER-stress marker responses under the tested conditions; no direct binding, iron-chelation potency, antifungal efficacy or clinical activity inferred.

Figure 2a; Figure 4a-d and caption; SI S8-S9 and captions; Results: Induction of ER stress in hepatic cancer-derived cell lines; Methods: Materials, Cell culture, XBP1 splicing test, quantitative PCR, Statistical analysis

Ratio of spliced to unspliced XBP1 after 6 h: PCR/MultiNA; Welch t test with Benjamini-Hochberg FDR adjustment. Figure 4 caption defines ***P < 0.001. — Figure 4a,b and caption; SI S8-S9; Results hepatic cancer-derived cell lines; Discussion on peculiar/biphasic ciclopirox response

GRP78 and CHOP mRNA relative to GAPDH after 24 h at 150 µM: qPCR normalized to GAPDH; Welch t test with Benjamini-Hochberg FDR adjustment. No exact bar heights inferred. — Figure 4c,d and caption; Methods: Quantitative polymerase chain reaction

Limited ER-stress marker response in primary human PXB hepatocytes

Cell-based study · Primary human hepatocytes (PXB cells) obtained from human-liver chimeric mice and treated in vitro [1]

At 150 µM for 24 h, ciclopirox did not significantly increase the XBP1 splicing ratio or GRP78 mRNA, but caused a small significant CHOP mRNA increase. Ciclosporin A and trimipramine increased the splicing ratio in the same experiment. The hepatocyte origin does not make this an animal treatment experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
XBP1 splicing ratio and GRP78/CHOP mRNA after 24 hQualitative response versus DMSO No significant increase in XBP1 splicing or GRP78 mRNA; a small CHOP mRNA increase (*P < 0.05).[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 times the 15 µM dataset concentration, corresponding to 150 µM (Figure 2a and Figure 5 caption).
Exposure duration
24 h
Method
In vitro exposure; PCR/MultiNA XBP1 splicing assay and qPCR of GRP78 and CHOP normalized to GAPDH.
Vehicle
DMSO control; final percentage not specified in inspected methods/captions.
Reported limits
No quantitative viability assay or exact marker effect sizes extracted. Figure caption reports representative results from at least two independent experiments without a complete replicate hierarchy.
Methods and source locations

Compound reported in the paper: Ciclopirox; Compound label in the paper: CPX; AdooQ A10213-10

Cellular ER-stress marker responses under the tested conditions; no direct binding, iron-chelation potency, antifungal efficacy or clinical activity inferred.

Figure 2a; Figure 5a,b and caption; SI S10 and caption; Results: Induction of ER stress in PXB cells; Methods: Materials, Cell culture, XBP1 splicing test, quantitative PCR

XBP1 splicing ratio and GRP78/CHOP mRNA after 24 h: PCR/MultiNA and GAPDH-normalized qPCR; Welch t test with Benjamini-Hochberg FDR adjustment. Figure 5 caption defines *P < 0.05. — Figure 5a,b and caption; Results: Induction of ER stress in PXB cells

Specifications

Manufacturer Adooq Bioscience
CAS Number 29342-05-0
Formula C12H17NO2
Molecular Weight 207.3
Synonyms Batrafen; Loprox; Mycoster; Stieprox; HOE 296b
SMILES
CC1=CC(=O)N(C(=C1)C2CCCCC2)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 36 mg/mL (173.68 mM)
Water Insoluble
Ethanol 36 mg/mL (173.68 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ciclopirox Research References

  1. [1] Katsuhisa Morita, Tadahaya Mizuno, Hiroyuki Kusuhara. Decomposition profile data analysis of multiple drug effects identifies endoplasmic reticulum stress-inducing ability as an unrecognized factor Scientific Reports (2020). PMID: 32753643 DOI: 10.1038/s41598-020-70140-9 Source material

Publications

1 publication citing this product

  1. Katsuhisa Morita, .et al. , Sci Rep, 2020, 10: 13139 PMID: 32753643

Added to your cart

View Cart Checkout
Loading...